

Resource Summary Report

Generated by [NIF](#) on Jul 31, 2026

pT3-EF1A-MYC-IRES-lucOS

RRID:Addgene_129776

Type: Plasmid

Proper Citation

RRID:Addgene_129776

Plasmid Information

URL: <http://www.addgene.org/129776>

Proper Citation: RRID:Addgene_129776

Insert Name: human MYC

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:31186238](#)

Vector Backbone Description: Vector Backbone:pT3-EF1a; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Comments: The plasmid contains loxp sites so it??s not ideal for experiments in mice expressing Cre.

Plasmid Name: pT3-EF1A-MYC-IRES-lucOS

Record Creation Time: 20220422T221721+0000

Record Last Update: 20260725T073802+0000

Ratings and Alerts

No rating or validation information has been found for pT3-EF1A-MYC-IRES-lucOS.

No alerts have been found for pT3-EF1A-MYC-IRES-lucOS.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Gong L, et al. (2025) Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy. *Cell*, 188(18), 5062.

Lindblad KE, et al. (2025) NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma. *Cancer discovery*, 15(3), 495.

Lei MML, et al. (2025) Wild-type KRAS activation drives evasion of interferon-mediated immunity and resistance to immunotherapy in hepatocellular carcinoma. *Nature communications*, 16(1), 9913.

Tzeng SF, et al. (2025) PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis. *Cancer discovery*, 15(8), 1676.

Zhu AX, et al. (2022) Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. *Nature medicine*, 28(8), 1599.